During recent communications, we have received this update from Lundbeck regarding Vyepti
To achieve optimum efficiency for patients and doctors Lundbeck Australia has decided to extend the Special Access Scheme (SAS) for Vyepti® (eptinezumab) until 31st December 2021 when last registrations will take place. Existing patients can continue on the program until 21st January 2022.
From 24th January 2022, Vyepti® will be available on private prescription from a treating neurologist with an estimated cost to patient of between $1,700 and $1,800 per quarter.
Lundbeck is progressing an application to the PBAC for PBS listing of Vyepti®.
We know the cost of Vyepti will be concerning for many of our members and supporters, as a private script Vyepti should be available on Non PBS Pharmaceuticals via your Extras on Private Health Insurance if you have it.
As soon as we have more news for you regarding Vyepti we will let you know. If you would like to read more about Vyepti and other CGRPs, visit https://www.migraine.org.au/cgrp
HELP US CONTINUE THE FIGHT BY DONATING TODAY!
Please donate what you can today so we can fight harder for the CGRPs. Every dollar counts! www.migraine.org.au/donate
You can also consider starting a donation appeal of your own on Facebook - it's easy to do! Simply click here! https://www.facebook.com/fund/migraineaus/
Do you like this post?